1. In Vivo
  2. >>Business Strategy

The Amplification of Roche Diagnostics

Roche Diagnostics may be ready to shed its second-class status in the diagnostics industry as its investments in innovative technology begin to bear fruit.

In 1990, when Roche Groupbrought in Jean-Luc Belingard to be head of its worldwide diagnostics division, he was given a mandate: The former head of Roche France was asked to take this small, unfocused business and turn it into a first-class diagnostics powerhouse.

Over the ensuing years, Belingard helped make significant changes within the company, restructuring the sales and marketing organization, reorganizing the product portfolio, and overhauling the company’s development programs to reflect...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.